wow, there must be news on that volume spike. I don't see it yet. When does my office get its Bloomberg terminal?! EDIT... ok I see the news TSLA and Intel execs joined the team. Luminar Technologies, Inc. (“Luminar” or “the Company”) (Nasdaq: LAZR), the global leader in automotive lidar hardware and software technology, today announced that two industry leaders have joined as executives: Alan Prescott as Chief Legal Officer, and Trey Campbell as Vice President of Investor Relations. Alan Prescott is an automotive and autonomous industry legal expert, engineer, and 20-year veteran from top OEM and technology companies. He will be responsible for directing all legal operations as Luminar’s Chief Legal Officer. Alan joins Luminar from Tesla, where he spent four years acting most recently as General Counsel. Prior to Tesla, he led Uber’s Advanced Technology Group’s legal team as senior counsel overseeing commercial, regulatory, litigation, privacy, and cybersecurity. Alan’s career began at Ford Motor Company as a safety engineer before receiving his law degree from Georgetown University, after which he spent over 10 years leading various legal operations within the automaker, concentrating on product development and manufacturing, as well as several years as Special Counsel to the General Counsel. “Alan is an outstanding addition to our executive team with an impressive track-record and deep experience leading and directing legal functions at a range of companies in our industry,” said Austin Russell, Founder and CEO of Luminar. “He understands the challenges and nuances of operating in both the autonomous driving space and in the automotive industry more broadly, and we look forward to his insights and expertise as we continue to scale our business and accelerate the expansion of our product and commercial roadmaps.” Trey Campbell will lead Luminar’s Investor Relations functions, acting as the primary liaison with Luminar shareholders and the financial community. Prior to joining Luminar, Trey was a 20-year veteran and financial executive of Intel Corporation. He began his career at Intel as a financial analyst in the Technology and Manufacturing group, later transitioning into Intel’s Business Groups, Corporate Strategy, Information Technology, Sales and Marketing, and has since served as Vice President of Investor Relations. During his tenure at Intel, Trey gained comprehensive expertise and fluency in managing corporate finance for existing and emerging technologies. Trey received his bachelor's degree from the University of Texas and his MBA from the University of Illinois. “Trey’s background in leading and growing an investor relations practice at a publicly traded global technology corporation will be invaluable to Luminar as we continue to execute on our near- and long-term initiatives to fulfill our vision,” said Tom Fennimore, Chief Financial Officer at Luminar. “Trey’s strong leadership and communication experience as well as long-standing relationships with the financial community will help tremendously as we spearhead the industry, creating shareholder value and taking Luminar to the next level.”
CVAC UPDATE**** The World Needs Our help here Folks.... 1. The Woes of Rivals The troubles of rivals AstraZeneca (NASDAQ:AZN) and Johnson & Johnson (NYSE:JNJ) offer CureVac an opportunity to become a leader in Europe. Several European countries temporarily suspended use of the AstraZeneca vaccine last month after some vaccinated individuals developed blood clots. Since, most countries have resumed AstraZeneca vaccinations -- but have limited use to certain age groups. As for J&J, it's delaying its vaccine launch in Europe. That's as U.S. regulators study cases of rare blood clots in some individuals who received its vaccine. And here's the worst news for J&J and AstraZeneca: Italian newspaper La Stampa reported the European Commission wouldn't renew vaccine contracts with both companies next year. At the same time, Europe's vaccination rollout has fallen behind. For example, only 18% of European Union residents have received at least one dose of a coronavirus vaccine. That compares to about 40% of U.S. residents. And residents of many European countries -- such has France -- are struggling to secure vaccine appointments because of supply shortages. CureVac already signed an advance purchase agreement with the European Commission for 225 million doses. The deal includes an option for 180 million additional doses. Considering Europe's vaccination situation, it's reasonable to imagine the countries ordering the extra doses -- and eventually more. 2. Logistic strength CureVac has more than just a vaccine. It has the ability to produce a great number of doses. In fact, CureVac already is manufacturing its vaccine so that it will be ready to meet demand if European regulators give it the nod. The company has made scaling up a priority. It plans to produce as many as 300 million doses this year and one billion doses next year. CureVac has in-house production capacity. But the company has also built out a manufacturing network including major names such as Wacker Chemie and Novartis. Working with a network of experts may minimize the risk of supply chain disruptions. And CureVac expects to open its own large-scale production facility in the second half of 2022. So, CureVac is setting itself up for success when it comes to delivering vaccines to customers. The company also has another logistic strength. And it has to do with the vaccine candidate itself. Like Moderna and Pfizer, CureVac has developed an mRNA vaccine. But CureVac's has easier storage requirements. It can be kept at standard refrigerator temperatures for at least three months. Moderna's can be stored at those temperatures for up to one month. Pfizer's vaccine may only stay in refrigerator temperatures for five days. This point could win over countries and healthcare systems that have struggled to distribute and store the Pfizer and Moderna vaccines. What does this mean for investors? CureVac could become a leader in the European coronavirus vaccine market. And that could lead to billions in revenue. A Reuters report late last year said the EU would pay 10 euros ($12.06) a dose for a CureVac vaccine. That means revenue of more than $2.7 billion from just the initial order. I like the revenue prospects. And I like CureVac's cash position. The company at the end of December had more than $1.59 billion. And it raised $517.5 million in a share sale earlier this year.////// Folks when this moves it's REALLY going to move.....
MASK WEARING CAN BE RELAXED IF YOU ARE VACCINATED-!!!!! EU AN ANNOUNCEMENT LIKE THAT FROM BIDEN WOULD SET THIS HOUSE ON FIRE!!!
GREAT NEWS!!! Ulla Johnson’s line of artisanal, ultra-feminine ready-to-wear items now available in biweekly or monthly payments, with no hidden or late fees Affirm, a more flexible and transparent alternative to credit cards, today announced a partnership with Ulla Johnson, the esteemed label of effortless, free-spirited womenswear. Now, eligible consumers can shop Ulla Johnson’s collection of refined, globally-inspired and meticulously constructed dresses, handbags, shoes and more, while paying over time. By selecting Affirm at checkout on UllaJohnson.com, approved customers can split the total cost of any purchase over $50 into biweekly or monthly payments with as low as 0% APR. Shoppers are shown the total cost of their purchase and will never pay more than they agree to upfront, as Affirm never charges any late or hidden fees. "From Meena Harris to Katie Holmes and Taylor Swift, Ulla Johnson’s collection has earned countless admirers," says Silvija Martincevic, Affirm’s Chief Commercial Officer. "Ulla Johnson devotees can now use Affirm to pay over time without hidden fees as they refresh their wardrobes... 2021 THEME FOR EVERYTHING! -BUY NOW PAY LATER